NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Lixte Biotechnology's Expanded Ovarian Cancer Trial with MD Anderson, GSK, and Northwestern University
TL;DR
Lixte Biotechnology's expanded collaboration with MD Anderson and GSK doubles patient enrollment, potentially accelerating development of its LB-100 compound for a competitive edge in ovarian cancer treatment.
Lixte Biotechnology's clinical trial adds Northwestern University as a second site, doubling enrollment to 42 patients to evaluate LB-100 combined with GSK's Dostarlimab for ovarian clear cell cancer.
This expanded trial could improve outcomes for ovarian cancer patients by advancing a new treatment paradigm that enhances therapies and offers hope for better survival rates.
Lixte's pioneering 'activation lethality' approach represents an entirely new field in cancer biology, with initial trial data expected to be presented in the first half of 2026.
Found this article helpful?
Share it with your network and spread the knowledge!
Lixte Biotechnology Holdings has expanded its clinical trial collaboration with MD Anderson Cancer Center and GSK by adding a second site at Northwestern University's Robert H. Lurie Comprehensive Cancer Center and doubling patient enrollment from 21 to 42 participants.
The trial is evaluating treatment for ovarian clear cell cancer, which is a specific subtype of ovarian cancer.
The trial is evaluating Lixte's proprietary compound LB-100 (a first-in-class PP2A inhibitor) in combination with GSK's Dostarlimab.
The trial involves Lixte Biotechnology Holdings, The University of Texas MD Anderson Cancer Center (led by Dr. Amir Jazaeri), GSK, and Northwestern University's Robert H. Lurie Comprehensive Cancer Center (led by Dr. Emily M. Hinchcliff).
The trial was initiated in January 2024, and data from the initial cohort is expected to be presented in the first half of 2026.
The trial is being conducted at two sites: The University of Texas MD Anderson Cancer Center and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
LB-100 is Lixte's first-in-class lead clinical PP2A inhibitor that has demonstrated anti-cancer activity and represents a pioneering approach in the new field of cancer biology called activation lethality, with potential to enhance chemotherapies and immunotherapies.
According to the content, proof-of-concept clinical trials are currently in progress for both Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
Additional information about LIXTE can be found at https://lixte.com/, and the full press release is available at https://ibn.fm/g1b2t.
BioMedWire is a specialized communications platform focused on biotechnology and life sciences that published this content, and it's part of the InvestorBrandNetwork that provides distribution services including wire solutions, editorial syndication, press release enhancement, and social media distribution.
Curated from InvestorBrandNetwork (IBN)
